Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelebiantumab plus TP chemotherapy as neoadjuvant therapy in locally advanced hypopharyngeal cancer (XMHNC-001)
ChiCTR2500109171Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in hypopharyngeal cancer, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Pathological complete response (pCR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2500109171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109171.